{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:05:46Z","timestamp":1778605546996,"version":"3.51.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Association of Rehabilitation Medicine","award":["2024JGYQ09"],"award-info":[{"award-number":["2024JGYQ09"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The combination of low-dose aspirin (LDA) and low-molecular-weight heparin (LMWH) is the standard of care for obstetric antiphospholipid syndrome (OAPS), significantly improving live birth rates. However, whether this regimen fully normalizes the pregnancy course and mitigates risks for both the mother and the neonate remains unclear. This study aimed to systematically evaluate whether significant maternal and neonatal morbidity persists in OAPS patients despite successful treatment and live birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 256 OAPS patients, including 166 criteria OAPS patients (C-OAPS\u2014patients who fulfilled both the clinical and laboratory criteria of the Sydney criteria) and 90 non-criteria OAPS patients (NC-OAPS\u2014patients who fulfilled only the clinical or only the laboratory criteria of the Sydney criteria) who achieved live birth, along with 768 matched healthy controls. We compared basic characteristics, laboratory parameters, and perinatal outcomes between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to healthy controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f768), treated OAPS patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f256) exhibited a persistent hypercoagulable state (elevated D-dimer and fibrin degradation product (FDP),\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01) and a higher incidence of anemia (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Their neonates had significantly lower birth weight (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006) and elevated risks of neonatal infection (adjusted OR\u202f=\u202f3.12,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004) and hyperbilirubinemia (adjusted OR\u202f=\u202f2.06,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.024), with the infection risk remaining significant in full-term infants. A subgroup analysis revealed no significant differences in obstetric history, maternal complications, comorbidities, and outcomes between the C-OAPS and NC-OAPS groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite standard treatment, OAPS patients who deliver successfully remain at an increased risk for persistent maternal hypercoagulability and adverse neonatal outcomes. These findings underscore the need for a paradigm shift in management\u2014from merely ensuring live birth to safeguarding neonatal health through proactive, multidisciplinary perinatal care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1660134","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:35:45Z","timestamp":1765348545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Maternal and neonatal outcomes in obstetric antiphospholipid syndrome: a retrospective case-control study"],"prefix":"10.3389","volume":"12","author":[{"given":"Lin","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1177\/0961203312440058","article-title":"The European registry on obstetric antiphospholipid syndrome (EUROAPS): a preliminary first year report","volume":"21","author":"Alijotas-Reig","year":"2012","journal-title":"Lupus"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0028-2243(91)90021-C","article-title":"Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies","volume":"41","author":"Out","year":"1991","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1182\/blood-2011-01-333617","article-title":"In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions","volume":"118","author":"Agostinis","year":"2011","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e000134","DOI":"10.1136\/lupus-2015-000134","article-title":"Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies","volume":"3","author":"Marder","year":"2016","journal-title":"Lupus Sci Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e42176","DOI":"10.1371\/journal.pone.0042176","article-title":"A role for toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome","volume":"7","author":"Gladigau","year":"2012","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20061022","article-title":"Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction","volume":"203","author":"Girardi","year":"2006","journal-title":"J Exp Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.4103\/0366-6999.207471","article-title":"Efficacy of different treatment regimens for antiphospholipid syndrome-related recurrent spontaneous abortion","volume":"130","author":"Ye","year":"2017","journal-title":"Chin Med J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/BOR.0b013e328344c3f7","article-title":"Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome)","volume":"23","author":"Hoppe","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/rheumatology\/kez419","article-title":"Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry","volume":"59","author":"Alijotas-Reig","year":"2020","journal-title":"Rheumatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.autrev.2018.12.006","article-title":"The European registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 1000 consecutive cases","volume":"18","author":"Alijotas-Reig","year":"2019","journal-title":"Autoimmun Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood-2013-08-522623","article-title":"Comparative incidence of pregnancy outcomes in treated obstetric 388 antiphospholipid syndrome: the NOH-APS observational study","volume":"123","author":"Bouvier","year":"2014","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/OGX.0000000000001033","article-title":"Recent advances in treatment of recurrent spontaneous abortion","volume":"77","author":"Deng","year":"2022","journal-title":"Obstet Gynecol Surv"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"106997","DOI":"10.1016\/j.medcli.2025.106997","article-title":"Diagnostic value of blood coagulation index in obstetric antiphospholipid syndrome and its subtypes","volume":"165","author":"Qi","year":"2025","journal-title":"Med Clin (Barc)"},{"key":"ref19","first-page":"4","article-title":"Clinical efficacy of low molecular weight heparin combined with expectant therapy in the treatment of preeclampsia","volume":"31","author":"Qiuling","year":"2023","journal-title":"Clin Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"337S","DOI":"10.1378\/chest.102.4_supplement.337s","article-title":"Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"102","author":"Hirsh","year":"1992","journal-title":"Chest"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.placenta.2023.06.013","article-title":"Correlation of placental lesions in patients with systemic lupus erythematosus, antiphospholipid syndrome and non-criteria obstetric antiphospholipid syndrome and adverse perinatal outcomes","volume":"139","author":"Castellanos Gutierrez","year":"2023","journal-title":"Placenta"},{"key":"ref22","first-page":"973","article-title":"Effect of different intervention time and intervention method for preventing preterm birth in APS with pregnancy","volume":"32","author":"Wenghui","year":"2016","journal-title":"Chin J Pract Gynecol Obstet"},{"key":"ref23","first-page":"44","article-title":"Efficacy and adverse effects of blue light irradiation supplemented by breastfeeding with breast milk fortification in the treatment of jaundice in preterm infants","volume":"44","author":"Sifeng","year":"2023","journal-title":"Jilin Yixue"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"Si4","DOI":"10.1093\/rheumatology\/kead603","article-title":"Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?","volume":"63","author":"Raschi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.medcli.2024.05.001","article-title":"Obstetric antiphospholipid syndrome","volume":"163","author":"Soto-Peleteiro","year":"2024","journal-title":"Med Clin (Barc)"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1660134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:35:46Z","timestamp":1765348546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1660134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":25,"alternative-id":["10.3389\/fmed.2025.1660134"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1660134","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1660134"}}